Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer.

Ebata Y, Ando K, Hasuda H, Mimori K, Unan EC, Pulukuri S, Tiku A, Berger A, Oki E, Bharti A, Yoshizumi T

DOI: 10.1002/1878-0261.70256
Published: 2026 Aug
Container: Molecular oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/1878-0261.70256,
  title = {Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer.},
  author = {Ebata Y and Ando K and Hasuda H and Mimori K and Unan EC and Pulukuri S and Tiku A and Berger A and Oki E and Bharti A and Yoshizumi T},
  year = {2026},
  journal = {Molecular oncology},
  doi = {10.1002/1878-0261.70256},
  url = {https://doi.org/10.1002/1878-0261.70256}
}

RIS

TY  - JOUR
TI  - Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer.
AU  - Ebata Y
AU  - Ando K
AU  - Hasuda H
AU  - Mimori K
AU  - Unan EC
AU  - Pulukuri S
AU  - Tiku A
AU  - Berger A
AU  - Oki E
AU  - Bharti A
AU  - Yoshizumi T
PY  - 2026
JO  - Molecular oncology
DO  - 10.1002/1878-0261.70256
UR  - https://doi.org/10.1002/1878-0261.70256
ER  -

APA

Y, E., K, A., H, H., K, M., EC, U., S, P., A, T., A, B., E, O., A, B., & T, Y. (2026). Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer.. Molecular oncology. https://doi.org/10.1002/1878-0261.70256

Source records

pubmed · retrieved 2026-09-25T06:26:07.408Z